Aberrant ENPP2 expression promotes tumor progression in multiple myeloma

References

• Rasche L, Kortüm KM, Raab MS, et al. The impact of tumor heterogeneity on diagnostics and novel therapeutic strategies in multiple myeloma. Int J Mol Sci. 2019;20(5):1248.
   PubMed Web of Science ®Google Scholar
• Panaroni C, Yee AJ, Raje NS. Myeloma and bone disease. Curr Osteoporos Rep. 2017;15(5):483–498.
   PubMed Web of Science ®Google Scholar
• Morris EV, Edwards CM. Bone marrow adiposity and multiple myeloma. Bone. 2019;118:42–46.
   PubMed Web of Science ®Google Scholar
• Delgado-Calle J, Anderson J, Cregor MD, et al. Bidirectional notch signaling and osteocyte-derived factors in the bone marrow microenvironment promote tumor cell proliferation and bone destruction in multiple myeloma. Cancer Res. 2016;76(5):1089–1100.
   PubMed Web of Science ®Google Scholar
• Łacina P, Butrym A, Humiński M, et al. Association of RANK and RANKL gene polymorphism with survival and calcium levels in multiple myeloma. Mol Carcinog. 2021;60(2):106–112.
   PubMed Web of Science ®Google Scholar
• Robak P, Węgłowska E, Dróżdż I, et al. Cytokine and chemokine profile in patients with multiple myeloma treated with bortezomib. Mediators Inflamm. 2020;2020:1–13.
   Web of Science ®Google Scholar
• Xu Y, Guo J, Liu J, et al. Hypoxia-induced CREB cooperates MMSET to modify chromatin and promote DKK1 expression in multiple myeloma. Oncogene. 2021;40(7):1231–1241.
   PubMed Web of Science ®Google Scholar
• Berenson A, Vardanyan S, David M, et al. Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib. Ann Hematol. 2017;96(3):449–459.
   PubMed Web of Science ®Google Scholar
• Xu J, Sun HY, Xiao FJ, et al. SENP1 inhibition induces apoptosis and growth arrest of multiple myeloma cells through modulation of NF-κB signaling. Biochem Biophys Res Commun. 2015;460(2):409–415.
   PubMed Web of Science ®Google Scholar
• Greenberg AJ, Rajkumar SV, Therneau TM, et al. Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma. Leukemia. 2014;28(2):398–403.
   PubMed Web of Science ®Google Scholar
• Sah JP, Hao NTT, Han X, et al. Ectonucleotide pyrophosphatase 2 (ENPP2) plays a crucial role in myogenic differentiation through the regulation by WNT/β-catenin signaling. Int J Biochem Cell Biol. 2020;118:105661.
   PubMed Web of Science ®Google Scholar
• Stracke ML, Krutzsch HC, Unsworth EJ, et al. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem. 1992;267(4):2524–2529.
   PubMed Web of Science ®Google Scholar
• Tripathi H, Al-Darraji A, Abo-Aly M, et al. Autotaxin inhibition reduces cardiac inflammation and mitigates adverse cardiac remodeling after myocardial infarction. J Mol Cell Cardiol. 2020;149:95–114.
   PubMed Web of Science ®Google Scholar
• Kaffe E, Magkrioti C, Aidinis V. Deregulated lysophosphatidic acid metabolism and signaling in liver cancer. Cancers. 2019;11(11):1626.
   PubMed Web of Science ®Google Scholar
• Lee SC, Fujiwara Y, Liu J, et al. Autotaxin and LPA1 and LPA5 receptors exert disparate functions in tumor cells versus the host tissue microenvironment in melanoma invasion and metastasis. Mol Cancer Res. 2015;13(1):174–185.
   PubMed Web of Science ®Google Scholar
• Magkrioti C, Oikonomou N, Kaffe E, et al. The autotaxin-lysophosphatidic acid axis promotes lung carcinogenesis. Cancer Res. 2018;78(13):3634–3644.
   PubMed Web of Science ®Google Scholar
• Quan M, Cui JJ, Feng X, et al. The critical role and potential target of the autotaxin/lysophosphatidate axis in pancreatic cancer. Tumour Biol. 2017;39(3):1010428317694544.
   Google Scholar
• Shim SJ, Shin E, Lee CS, et al. The expressions of autotaxin-lysophosphatidate signaling-related proteins in metastatic breast cancer. Int J Clin Exp Pathol. 2019;12(8):2920–2930.
   PubMed Web of Science ®Google Scholar
• Kaffe E, Katsifa A, Xylourgidis N, et al. Hepatocyte autotaxin expression promotes liver fibrosis and cancer. Hepatology. 2017;65(4):1369–1383.
   PubMed Web of Science ®Google Scholar
• Amaral RF, Geraldo LHM, Einicker-Lamas M, et al. Microglial lysophosphatidic acid promotes glioblastoma proliferation and migration via LPA1 receptor. J Neurochem. 2021;156(4):499–512.
   PubMed Web of Science ®Google Scholar
• Tang X, Benesch MGK, Brindley DN. Role of the autotaxin-lysophosphatidate axis in the development of resistance to cancer therapy. Biochim Biophys Acta Mol Cell Biol Lipids. 2020;1865(8):158716.
   PubMed Web of Science ®Google Scholar
• Sasagawa T, Okita M, Murakami J, et al. Abnormal serum lysophospholipids in multiple myeloma patients. Lipids. 1999;34(1):17–21.
   PubMed Web of Science ®Google Scholar
• Li QF, Wu CT, Duan HF, et al. Activation of sphingosine kinase mediates suppressive effect of interleukin-6 on human multiple myeloma cell apoptosis. Br J Haematol. 2007;138(5):632–639.
   PubMed Web of Science ®Google Scholar
• Harmer D, Falank C, Reagan MR. Interleukin-6 interweaves the bone marrow microenvironment, bone loss, and multiple myeloma. Front Endocrinol. 2018;9:788.
   PubMed Web of Science ®Google Scholar
• Giuliani N, Ferretti M, Bolzoni M, et al. Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation. Leukemia. 2012;26(6):1391–1401.
   PubMed Web of Science ®Google Scholar
• Hannun YA, Obeid LM. Sphingolipids and their metabolism in physiology and disease. Nat Rev Mol Cell Biol. 2018;19(3):175–191.
   PubMed Web of Science ®Google Scholar
• Tang X, Benesch MG, Brindley DN. Lipid phosphate phosphatases and their roles in mammalian physiology and pathology. J Lipid Res. 2015;56(11):2048–2060.
   PubMed Web of Science ®Google Scholar
• Firth J. Haematology: multiple myeloma. Clin Med. 2019;19(1):58–60.
   PubMed Web of Science ®Google Scholar
• Nikolova-Vlahova MK, Kamburova M, Hristova J, et al. Biclonal myeloma in renal failure. Cent Eur J Immunol. 2020;45(1):122–124.
   PubMed Web of Science ®Google Scholar
• Roodman GD. Pathogenesis of myeloma bone disease. Leukemia. 2009;23(3):435–441.
   PubMed Web of Science ®Google Scholar
• Ninou I, Magkrioti C, Aidinis V. Autotaxin in pathophysiology and pulmonary fibrosis. Front Med. 2018;5:180.
   Web of Science ®Google Scholar
• Banerjee S, Norman DD, Lee SC, et al. Highly potent Non-Carboxylic acid autotaxin inhibitors reduce melanoma metastasis and chemotherapeutic resistance of breast cancer stem cells. J Med Chem. 2017;60(4):1309–1324.
   PubMed Web of Science ®Google Scholar
• Federico L, Jeong KJ, Vellano CP, et al. Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progression. J Lipid Res. 2016;57(1):25–35.
   PubMed Web of Science ®Google Scholar
• Kawaguchi M, Okabe T, Okudaira S, et al. Identification of potent in vivo autotaxin inhibitors that bind to both hydrophobic pockets and channels in the catalytic domain. J Med Chem. 2020;63(6):3188–3204.
   PubMed Web of Science ®Google Scholar
• Tigyi GJ, Yue J, Norman DD, et al. Regulation of tumor cell - Microenvironment interaction by the autotaxin-lysophosphatidic acid receptor axis. Adv Biol Regul. 2019;71:183–193.
   PubMedGoogle Scholar